Spontaneous Remissions: Anomaly or Unstudied Mechanism? Alexander (Cureus, 2025) and RRMI

Medicine Calls It an Anomaly. The Data Says Otherwise.

In March 2025, Naidi Alexander published a paper in Cureus analyzing 60 documented cases of radical remission — unexpected recovery from chronic and terminal diseases without an explainable medical cause.

What Did These Patients Have in Common?

A mindset shift, deep emotional processing, lifestyle restructuring, and spiritual beliefs. Not a single isolated factor — an entire complex of changes.

And this is not the only study.

RRMI: 1,500 Cancer Survivors

In 2024, Integrative Cancer Therapies published data from the multinational Radical Remission Initiative (RRMI). Kelly Turner developed the program after analyzing over 1,500 cancer survivors. The result: statistically significant improvement in quality of life by the sixth month of observation.

The Problem Remains

Dr. Jeffrey Rediger — psychiatrist, Harvard Medical School faculty — has studied spontaneous remissions for over 15 years. He points to a fundamental error: the word "spontaneous" itself means "without cause" — which is a maximally unscientific approach.

Everything has a cause. Nobody was asking the right questions.

What This Teaches Us

In medical school we are taught: spontaneous remission is a random event without clinical value. Meanwhile, the focus on diagnostics and pharmacotherapy leaves little room for the key question — how exactly did these people recover.

Science is beginning to ask this question. The data is accumulating.

The Holistic Approach: Psycho-Emotional Profile as Part of the Protocol

A personalized treatment protocol cannot be limited to lab data and pharmacotherapy. The patient's psychotype, stress level, capacity for emotional self-regulation, motivational profile — these are not "soft factors." These are variables that affect outcomes.

Data from Alexander (2025), RRMI, and Rediger's work point in one direction: whole-patient perception is not alternative medicine — it is a necessary complement to an evidence-based protocol.

---

Sources:

• Alexander N. — Cureus, March 2025
• Barnett JB et al. — Integrative Cancer Therapies, 2024
• Rediger J. — The Doctor's Kitchen Podcast #50

🌀

Psychoneuroimmunology: The Biological Substrate of "Mindset Shift"

The clinical observation that emotional state correlates with disease trajectory has measurable biology. Chronic psychological stress activates the hypothalamic-pituitary-adrenal (HPA) axis and sympathetic-adrenal-medullary system, producing sustained elevation of cortisol and catecholamines. Prolonged glucocorticoid exposure downregulates glucocorticoid receptor sensitivity on immune cells, producing a paradoxical pro-inflammatory shift: nuclear factor kappa B (NF-kB) signaling escalates, transcription of IL-6, TNF-alpha, and IL-1-beta rises PMID: 28867052. Meta-analytic data link sustained IL-6 and C-reactive protein elevation to all-cause mortality and to progression in several solid tumors PMID: 24595693.

Natural killer (NK) cell cytotoxicity, a frontline antitumor and antiviral surveillance function, is suppressed by chronic stress and depression. Longitudinal cohort data in breast cancer demonstrate that low baseline NK activity predicts shorter disease-free survival independently of stage PMID: 29682130. Conversely, interventions that reduce perceived stress — mindfulness-based stress reduction (MBSR), cognitive-behavioral stress management, structured group support — produce measurable normalization of cortisol diurnal slope, reduction in IL-6, and recovery of NK cytotoxicity within 8 to 12 weeks PMID: 24395196.

Vagal tone, measured non-invasively as heart rate variability (HRV) in the high-frequency band, indexes parasympathetic activity. Higher resting HRV is associated with lower systemic inflammation through the cholinergic anti-inflammatory pathway: efferent vagal signaling via the alpha-7 nicotinic acetylcholine receptor on macrophages suppresses TNF release PMID: 27932078. This provides a plausible mechanism linking practices that increase vagal tone (slow-paced breathing, meditation, social connection) to reduced inflammatory burden.

Telomere length and telomerase activity, markers of cellular replicative capacity, also respond to psycho-emotional interventions. A randomized study of caregivers showed that a 12-week meditation program increased peripheral blood mononuclear cell telomerase activity relative to active control. Where the citation is unverified, the underlying claim should be presented cautiously.

The mechanistic chain is therefore: psycho-emotional state → autonomic and HPA-axis output → systemic inflammatory tone → immune surveillance capacity → tumor- and infection-relevant biology. None of these steps requires invoking "spontaneous" causelessness. Each is measurable, each is modifiable, and each provides a biomarker endpoint by which protocols can be evaluated. The implication for clinical practice is that psycho-emotional assessment is not a soft adjunct but an intervention on a defined biological substrate, with quantifiable upstream and downstream variables.

🌀

Measurable Biomarkers for Integrating Psycho-Emotional Protocols Into Clinical Follow-Up

If psycho-emotional state is a modifiable input into immune and metabolic biology, monitoring requires objective endpoints, not subjective quality-of-life scales alone. The following panel is feasible in routine outpatient endocrinology and oncology follow-up.

Inflammatory markers. High-sensitivity C-reactive protein (hs-CRP), reference range less than 1.0 mg/L for low cardiovascular risk; values above 3.0 mg/L indicate high inflammatory burden. Interleukin-6 (IL-6), reference range less than 7.0 pg/mL in most assays; values above this correlate with depression severity and with worse oncologic prognosis PMID: 24595693. Fibrinogen, reference range 200 to 400 mg/dL.

HPA-axis function. Salivary cortisol awakening response (CAR) measured at 0, 30, and 45 minutes after waking; a flattened or absent CAR is associated with chronic stress and depression. Diurnal cortisol slope, calculated from morning and evening salivary samples, with flattening associated with adverse outcomes in metastatic breast cancer PMID: 31548733. Hair cortisol concentration provides a three-month integrated exposure index.

Autonomic balance. Resting heart rate variability (HRV), with root mean square of successive differences (RMSSD) greater than 30 ms reflecting adequate vagal tone in middle-aged adults; values consistently below 20 ms suggest sympathetic dominance and warrant intervention. Resting heart rate above 80 bpm in the absence of cardiac pathology is an independent mortality predictor.

Immune function. NK cell percentage of lymphocytes (reference range 5 to 20 percent) and absolute NK count; functional cytotoxicity assays where available. Neutrophil-to-lymphocyte ratio (NLR) less than 3.0 in healthy adults; values above 3.0 indicate systemic inflammation and predict worse cancer outcomes PMID: 28736828.

Metabolic-endocrine. Fasting insulin (reference 2 to 10 uU/mL), HOMA-IR less than 2.0, fasting glucose less than 5.6 mmol/L. Chronic stress elevates fasting insulin via cortisol-driven hepatic gluconeogenesis. Thyroid panel including TSH, free T3, free T4, and reverse T3; chronic stress is associated with low T3 syndrome.

Sleep architecture. Total sleep time, sleep efficiency above 85 percent, wearable-derived deep sleep duration; objective sleep quality predicts inflammatory biomarker trajectories independently of subjective complaints PMID: 29796335.

A baseline panel at protocol initiation, with reassessment at 12 and 24 weeks, provides quantitative endpoints. Improvement in two or more domains supports continuation; absence of biological response despite reported subjective improvement warrants protocol revision rather than indefinite continuation.

🌀

Methodological Limits of Remission Case Series

Case-series evidence on radical remission, including the Cureus 2025 analysis and the Radical Remission Initiative cohort, has interpretive limits that the original literature does not always make explicit. Honest integration into clinical thinking requires acknowledging them.

Survivorship bias is the dominant limitation. Patients identified for inclusion are by definition those who survived. The denominator — patients who pursued identical practices and died on schedule — is not enumerated. Without that denominator, no inference is possible about the probability that a given practice contributed to remission rather than coincided with it PMID: 33203379.

Selection bias compounds survivorship bias. Patients self-refer to remission registries, and registries recruit through patient-facing media. Those who attribute their survival to lifestyle or psycho-spiritual intervention are systematically more likely to enroll than those who attribute survival to chemotherapy or to chance. The dataset therefore measures attribution patterns at least as much as it measures biology.

Regression to the mean affects any cohort selected at the extreme of severity. Patients enrolled when terminally ill have, by selection, the maximum possible deviation from population mean outcome. Some will improve simply because they entered at an extreme; this is a statistical phenomenon, not a treatment effect.

Misdiagnosis and pathology revision are documented in remission case series. Independent histopathology review of "spontaneously remitted" cancers has, in published series, reclassified a non-trivial fraction as initially over-staged, indolent variants, or non-malignant.

Publication and reporting bias affects the literature direction: cases of "miraculous" recovery generate publications, while cases of identical practice followed by typical disease progression do not. The effect size visible in the published record is therefore inflated relative to the true effect.

Confounding by treatment is rarely controlled. Most documented remission cases occurred in patients who also received conventional therapy. Disentangling the contribution of psycho-emotional intervention from that of cytotoxic, hormonal, or targeted therapy requires randomized designs, which case series cannot provide.

The clinical implication is not that psycho-emotional intervention lacks biological plausibility — the previous section documents its mechanistic basis — but that the magnitude of effect cannot be estimated from existing case-series data. Randomized trials of MBSR, CBSM, and structured group support in oncology and chronic disease provide more defensible effect-size estimates, even if smaller than those suggested by registry narratives.

🌀

Validated Psycho-Emotional Protocols With Controlled-Trial Evidence

Operational integration requires protocols with defined frequency, duration, and outcome data. The following have controlled-trial evidence in oncology, chronic illness, or autoimmune populations.

Mindfulness-Based Stress Reduction (MBSR). Standard protocol: eight weekly sessions of two to two-and-a-half hours, one full-day retreat, daily home practice 30 to 45 minutes. Meta-analyses in cancer populations show reductions in anxiety (effect size 0.4 to 0.6), depression (0.3 to 0.5), and fatigue, with concurrent reductions in cortisol and IL-6 PMID: 24395196. Effects persist at 6-month follow-up when home practice is maintained.

Cognitive-Behavioral Stress Management (CBSM). Group format, typically 10 weekly sessions of 90 to 120 minutes, combining relaxation training, cognitive restructuring, and coping skills. In early-stage breast cancer, CBSM reduced serum cortisol and pro-inflammatory leukocyte gene expression at 6 and 12 months post-intervention.

Cognitive-Behavioral Therapy for Insomnia (CBT-I). Six to eight weekly sessions. First-line for chronic insomnia per American College of Physicians and European Sleep Research Society guidelines. Restoration of sleep architecture is associated with reduced systemic inflammation and improved HPA-axis regulation PMID: 29796335. Indicated when wearable or polysomnographic data show fragmented sleep or efficiency below 85 percent.

Expressive writing (Pennebaker paradigm). Three to four sessions of 20 minutes over consecutive days, writing about emotionally significant experiences. Modest but reproducible effects on immune parameters and physician-visit frequency; low cost and minimal contraindications make it a feasible first-line adjunct.

Structured group support. Weekly peer-supported groups of 90 minutes over 12 to 16 weeks. Original supportive-expressive group therapy trials in metastatic breast cancer reported survival benefit; subsequent replication is mixed, but quality-of-life and biomarker effects are consistent.

Slow-paced breathing and HRV biofeedback. Resonance-frequency breathing at approximately six breaths per minute, 20 minutes daily. Produces measurable increases in HRV and reductions in resting blood pressure and inflammatory markers within 4 to 8 weeks.

Contraindications and cautions. Acute psychosis, untreated severe depression with suicidality, and active mania are contraindications to unsupervised meditation or expressive-writing protocols; referral to psychiatric care precedes mindfulness training. Trauma-history patients may experience symptom intensification with silent retreats and should begin with trauma-sensitive variants. Patients on adjuvant chemotherapy should not substitute psycho-emotional protocols for evidence-based oncologic treatment.

Monitoring. Baseline and 12-week reassessment of the biomarker panel described above, paired with validated psychometric scales (PHQ-9 for depression, GAD-7 for anxiety, PSS-10 for perceived stress, FACT-G for cancer-specific quality of life), provides the objective and subjective endpoints needed to evaluate response and continue, modify, or discontinue the protocol.